ASCLETIS-B (01672) rose over 3%, with cumulative gains exceeding 100% over the past month. As of press time, the stock was up 3.49% to HK$18.36, with trading volume of HK$142 million.

On the news front, on August 15, ASCLETIS-B released its interim results for the six months ended June 30, 2025. The group achieved total revenue of RMB 104 million, representing a year-on-year increase of 111.4%. Research and development costs reached RMB 147 million, up 10.9% year-on-year. Loss attributable to equity shareholders of the company was RMB 87.95 million, down 32.5% year-on-year. Loss per share was RMB 0.0914.

During the reporting period and up to the date of this announcement, the group made significant progress in its metabolic disease pipeline, immune disease pipeline, and expanded indication product pipeline:

ASC30 once-daily oral tablets for obesity treatment: In the US Phase Ib study, after 28 days of treatment, the placebo-adjusted mean weight loss from baseline reached up to 6.5%, demonstrating its potential to become a best-in-class candidate drug for obesity treatment. The group initiated a US Phase IIa study and rapidly completed enrollment of 125 subjects within just over one month.

ASC30 monthly or less frequent subcutaneous injection for obesity treatment: In the US Phase Ib study, a single subcutaneous injection demonstrated a 36-day half-life in obese patients, supporting monthly or less frequent dosing.